Majid Farshdousti Hagh
Overview
Explore the profile of Majid Farshdousti Hagh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taghinejad Z, Kazemi T, Fadaee M, Farshdousti Hagh M, Solali S
Biochem Biophys Res Commun
. 2023 Aug;
678:135-143.
PMID: 37634411
Hematological malignancies(HMs) are highly heterogeneous diseases with globally rising incidence. Despite major improvements in the management of HMs, conventional therapies have limited efficacy, and relapses with high mortality rates are...
2.
Mirzapour M, Farshdousti Hagh M, Marofi F, Solali S, Alaei A
Biochem Biophys Res Commun
. 2023 Jul;
676:13-20.
PMID: 37480688
Introduction: T-cell acute lymphoblastic leukemia is characterized by its fast progression rate and high complications. TRAIL can be used to trigger apoptosis in cancer cells with minimal effects on normal...
3.
Zaka Khosravi S, Ramshe S, Farsani M, Moonesi M, Marofi F, Farshdousti Hagh M
J Recept Signal Transduct Res
. 2023 May;
43(2):50-61.
PMID: 37186553
The angiogenesis efficacy in solid tumors and hematological malignancies has been identified for more than twenty years. Although the exact role of angiogenesis in leukemia as a common hematological malignancy...
4.
Sajjadi-Dokht M, Merza Mohamad T, Rahman H, Maashi M, Danshina S, Shomali N, et al.
Genes Dis
. 2022 Jun;
9(4):849-867.
PMID: 35685482
Blood disorders include a wide spectrum of blood-associated malignancies resulting from inherited or acquired defects. The ineffectiveness of existing therapies against blood disorders arises from different reasons, one of which...
5.
Zeinalzadeh E, Valerievich Yumashev A, Rahman H, Marofi F, Shomali N, Kafil H, et al.
Front Genet
. 2022 Jan;
12:703883.
PMID: 34992627
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway has been known to be involved in cell growth, cellular differentiation processes development, immune cell survival, and hematopoietic...
6.
Zaka Khosravi S, Ramshe S, Farsani M, Solali S, Moonesi M, Farshdousti Hagh M
Blood Res
. 2021 May;
56(2):79-85.
PMID: 34031276
Background: Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children. Several environmental and genetic factors are known to be involved in its development and progression. The...
7.
Marofi F, Shomali N, Younus L, Hassanzadeh A, Vahedi G, Kuznetsova M, et al.
Biotechnol Appl Biochem
. 2021 Mar;
69(2):822-839.
PMID: 33786874
Mesenchymal stem cells (MSCs) are one of the most prominent cells in the bone marrow. MSCs can affect acute lymphocytic leukemia (ALL) cells under hypoxic conditions. With this aim, we...
8.
Moonesi M, Zaka Khosravi S, Ramshe S, Farsani M, Solali S, Mohammadi M, et al.
J Cell Physiol
. 2020 Nov;
236(6):4097-4105.
PMID: 33184857
Multiple factors, including growth factors, are shown to be culprits of cancer outset and persistence. Among growth factors, insulin-like growth factors (IGFs) family are of more importance in the prognosis...
9.
Rahimzadeh S, Rahbarghazi R, Aslani S, Rajabi H, Latifi Z, Farshdousti Hagh M, et al.
Bioimpacts
. 2020 Sep;
10(4):243-250.
PMID: 32983940
Nowadays, mesenchymal stem cells are touted as suitable cell supply for the restoration of injured bone tissue. The existence of osteogenic differentiation makes these cells capable of replenishing damaged cells...
10.
Shojaei Moghadam K, Farshdousti Hagh M, Alivand M, Fardi M, Movassaghpour A, Mohammadi A, et al.
Adv Pharm Bull
. 2020 Feb;
10(1):81-87.
PMID: 32002365
Sepantronium bromide (YM155) is a Survivin inhibitor which recently advanced as an anticancer agent in phase II clinical trials. Survivin belongs to IAP (inhibitor of apoptosis) gene family and is...